A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)
2024 · Clinical Diabetes and Endocrinology · 1 citations
https://doi.org/10.1186/s40842-024-00210-8